Nitric oxide and cardiovascular and renal effects

Osteoarthritis and Cartilage

Volumn 16, Issue SUPPL. 2, 2008, Pages

  Raij, Leopoldo ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

angiotensin II; atherosclerosis; hypertension; kidney; Nitric oxide; NO donors

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GUANYLATE CYCLASE; HYDROGEN PEROXIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE; VASCULAR CELL ADHESION MOLECULE 1;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONCENTRATION (PARAMETERS); DRUG MECHANISM; DRUG RESEARCH; ENZYME ACTIVATION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NITROSYLATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOSIS PREVENTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 51349140430     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(08)60009-6     Document Type: Article

References (51)

1. Landmesser U., Hornig B., and Drexler H. Endothelial function: a critical determinant in atherosclerosis?. Circulation 109 (2004) II27-II33
2. Mayer B., Pfeiffer S., Schrammel A., Koesling D., Schmidt K., and Brunner F. A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 273 (1998) 3264-3270
3. Gladwin M.T., Schechter A.N., Kim-Shapiro D.B., Patel R.P., Hogg N., Shiva S., et al. The emerging biology of the nitrite anion. Nat Chem Biol 1 (2005) 308-314
4. Kelm M., Dahmann R., Wink D., and Feelisch M. The nitric oxide/superoxide assay. Insights into the biological chemistry of the NO/O-2. interaction. J Biol Chem 272 (1997) 9922-9932
5. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 37 (2001) 767-773
6. Raij L. Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin Nephrol 19 (1999) 296-303
7. Ganten D., Hermann K., Unger T., and Lang R.E. The tissue renin-angiotensin systems: focus on brain angiotensin, adrenal gland and arterial wall. Clin Exp Hypertens A 5 (1983) 1099-1118
8. Navar L.G., Imig J.D., Zou L., and Wang C.T. Intrarenal production of angiotensin II. Semin Nephrol 17 (1997) 412-422
9. Ziegler T., Silacci P., Harrison V.J., and Hayoz D. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 32 (1998) 351-355
10. Awolesi M.A., Widmann M.D., Sessa W.C., and Sumpio B.E. Cyclic strain increases endothelial nitric oxide syn-thase activity. Surgery 116 (1994) 439-444 discussion 444-435.
11. Moncada S., and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012
12. Takemoto M., Egashira K., Usui M., Numaguchi K., Tomita H., Tsutsui H., et al. Important role of tissue angioten-sin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes nduced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99 (1997) 278-287
13. Goodfriend T.L., Elliott M.E., and Catt K.J. Angiotensin receptors and their antagonists. N Engl J Med 334 (1996) 1649-1654
14. Ichiki T., Usui M., Kato M., Funakoshi Y., Ito K., Egashira K., et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 31 (1998) 342-348
15. Usui M., Ichiki T., Katoh M., Egashira K., and Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 32 (1998) 527-533
16. Doughan A.K., Harrison D.G., and Dikalov S.I. Molecular Mechanisms of Angiotensin II Mediated Mitochondrial Dysfunction. Linking Mitochondrial Oxidative Damage and Vascular Endothelial Dysfunction. Circ Res (2007)
17. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 (2001) E14-E22
18. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., Oelze M., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90 (2002) E58-E65
19. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 387 (2006) 1521-1533
20. Webb D.J. Endothelin: from molecule to man. Br J Clin Pharmacol 44 (1997) 9-20
21. Mathew V., Hasdai D., and Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 71 (1996) 769-777
22. Haynes W.G., and Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hyper-tens 16 (1998) 1081-1098
23. Bouallegue A., Daou G.B., and Srivastava A.K. Nitric oxide attenuates endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 in vascular smooth muscle cells by a cGMP-dependent pathway. Am J Physiol Heart Circ Physiol 293 (2007) H2072-H2079
24. Chen Y., McCarron R.M., Golech S., Bembry J., Ford B., Lenz F.A., et al. ET-1-and NO-mediated signal trans-duction pathway in human brain capillary endothelial cells. Am J Physiol Cell Physiol 284 (2003) C243-C249
25. Dong F., Zhang X., Wold L.E., Ren Q., Zhang Z., and Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145 (2005) 323-333
26. Ramzy D., Rao V., Tumiati L.C., Xu N., Sheshgiri R., Miriuka S., et al. Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation 114 (2006) I319-I326
27. Usui M., Egashira K., Kitamoto S., Koyanagi M., Katoh M., Kataoka C., et al. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 34 (1999) 546-551
28. Hayakawa H., Coffee K., and Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 96 (1997) 2407-2413
29. Hayakawa H., and Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 29 (1997) 235-241
30. Chu Y., Iida S., Lund D.D., Weiss R.M., DiBona G.F., Watanabe Y., et al. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Circ Res 92 (2003) 461-468
31. Zhou M.S., Adam A.G., Jaimes E.A., and Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 42 (2003) 945-951
32. Topper J.N., Cai J., Falb D., and Gimbrone Jr. M.A. Identifcation of vascular endothelial genes differentially responsive to fuid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 93 (1996) 10417-10422
33. Stamler J., Mendelsohn M.E., Amarante P., Smick D., Andon N., Davies P.F., et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 65 (1989) 789-795
34. Pigazzi A., Heydrick S., Folli F., Benoit S., Michelson A., and Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem 274 (1999) 14368-14375
35. Wilcox J.N., Subramanian R.R., Sundell C.L., Tracey W.R., Pollock J.S., Harrison D.G., et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17 (1997) 2479-2488
36. Kuhlencordt P.J., Gyurko R., Han F., Scherrer-Crosbie M., Aretz T.H., Hajjar R., et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104 (2001) 448-454
37. Kobayashi T., Tahara Y., Matsumoto M., Iguchi M., Sano H., Murayama T., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-defcient mice. J Clin Invest 114 (2004) 784-794
38. Zhou M.S., Schulman I.H., Pagano P.J., Jaimes E.A., and Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47 (2006) 81-86
39. Iwai M., Chen R., Li Z., Shiuchi T., Suzuki J., Ide A., et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112 (2005) 1636-1643
40. Hu C., Dandapat A., Chen J., Liu Y., Hermonat P.L., Carey R.M., et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis (2007)
41. Hayakawa H., and Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 31 (1998) 266-270
42. Noiri E., Satoh H., Taguchi J., Brodsky S.V., Nakao A., Ogawa Y., et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40 (2002) 535-540
43. Patzak A., Mrowka R., Storch E., Hocher B., and Persson P.B. Interaction of angiotensin II and nitric oxide in isolated perfused afferent arterioles of mice. J Am Soc Nephrol 12 (2001) 1122-1127
44. Patzak A., Steege A., Lai E.Y., Brinkmann J.O., Kupsch E., Spielmann N., et al. Angiotensin II response in afferent arterioles of mice lacking either the endothelial or neuronal isoform of nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 294 (2008) R429-R437
45. Patzak A., and Persson A.E. Angiotensin II-nitric oxide interaction in the kidney. Curr Opin Nephrol Hypertens 16 (2007) 46-51
46. Arendshorst W.J., Brannstrom K., and Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 10 Suppl 11 (1999) S149-S161
47. Duke L.M., Widdop R.E., Kett M.M., and Evans R.G. AT(2) receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. Br J Pharmacol 144 (2005) 486-492
48. Stegbauer J., Vonend O., Habbel S., Quack I., Sellin L., Gross V., et al. Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. J Hypertens 23 (2005) 1691-1698
49. Welch W.J., Blau J., Xie H., Chabrashvili T., and Wilcox C.S. Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol 288 (2005) H22-H28
50. McEniery C.M., Schmitt M., Qasem A., Webb D.J., Avolio A.P., Wilkinson I.B., et al. Nebivolol increases arterial dis-tensibility in vivo. Hypertension 44 (2004) 305-310
51. John S., and Schmieder R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 18 (2000) 363-374